Safety and effectiveness of abatacept in Japanese non-elderly and elderly patients with rheumatoid arthritis in an all-cases post-marketing surveillance

Masayoshi HarigaiDivision of Epidemiology and Pharmacoepidemiology, Department of Rheumatology, School of Medicine, Tokyo Women’s Medical University, Tokyo, Japan; Correspondence[email protected]

Naoki IshiguroGraduate School & Faculty of Medicine, Nagoya University School of Medicine, Nagoya, Japan;

Shigeko InokumaChiba Central Medical Center, Chiba, Japan;

Tsuneyo MimoriKyoto University Graduate School of Medicine, Kyoto, Japan;

Junnosuke RyuNihon University School of Medicine, Tokyo, Japan;

Syuji TakeiFaculty of Medicine, Kagoshima University School of Health Science, Kagoshima, Japan;

Tsutomu TakeuchiKeio University School of Medicine, Tokyo, Japan;

Yoshiya TanakaUniversity of Occupational and Environmental Health, Fukuoka, Japan;

Yoshinari TakasakiJuntendo University School of Medicine, Tokyo, Japan;

Hisashi YamanakaDivision of Epidemiology and Pharmacoepidemiology, Department of Rheumatology, School of Medicine, Tokyo Women’s Medical University, Tokyo, Japan;

Yuri YoshizawaBristol-Myers Squibb K.K., Tokyo, Japan;

Ichino ChinenBristol-Myers Squibb K.K., Tokyo, Japan;

Toru NakaoBristol-Myers Squibb K.K., Tokyo, Japan;

Takao KoikeSapporo Medical Center NTT EC, Sapporo, Japan

show all

Safety and effectiveness of abatacept in Japanese non-elderly and elderly patients with rheumatoid arthritis in an all-cases post-marketing surveillance

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Safety and effectiveness of abatacept in Japanese non-elderly and elderly patients with rheumatoid arthritis in an all-cases post-marketing surveillance

Reprints and Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date